News Stories

FDA approves smaller leadless pacemaker from Abbott

The U.S. Food and Drug Administration (FDA) has approved Abbott's Aveir VR Mini Ventricular leadless pacemaker (LP).

ESC 2026: targeted lead placement is no better than standard placement in CRT

Targeted placement of a left ventricular lead does not improve outcomes in patients with heart failure undergoing cardiac resynchronisation therapy (CRT), according to results presented at the European Society of Cardiology (ESC) congress (28–31 August, Munich, Germany) and published simultaneously in The Lancet.

ESC 2026: ICDs may benefit certain younger patients with mild-to-moderate heart dysfunction

While younger patients appeared to benefit, implantable cardioverter-defibrillators (ICDs) did not improve the primary endpoint overall in the CMR GUIDE trial, according to new data presented at the European Society of Cardiology (ESC) congress (28–31 August, Munich, Germany) and published simultaneously in the Journal of the American Medical Association (JAMA).

His-Alternative II: Conduction-System Pacing Holds Up Well in CRT-Treated HFrEF

Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.

Targeted lead placement fails to improve outcomes for heart failure patients undergoing CRT

The DANISH-CRT trial compared targeted placement of the left ventricular pacing lead with standard placement.